炎症性肠病患者使用生物制剂与免疫抑制剂相关的淋巴瘤风险:全国性巢式病例对照研究
该研究基于法国国家健康数据系统2009至2024年IBD患者队列,开展巢式病例对照研究,纳入1238例淋巴瘤病例与52565例匹配对照。结果显示当前使用硫嘌呤类(aOR 2.36)和抗TNF(aOR 1.72)与淋巴瘤风险升高相关,联合用药风险超过三倍(aOR 3.44);维得利珠单抗、乌司奴单抗和JAK抑制剂未观察到风险增加。
要点
- 当前使用硫嘌呤类或抗TNF与IBD患者淋巴瘤风险升高相关
- 抗TNF联合硫嘌呤/甲氨蝶呤时淋巴瘤风险超过三倍
- 维得利珠单抗、乌司奴单抗和JAK抑制剂未显示淋巴瘤风险增加
核心结论
- 硫嘌呤类和抗TNF与IBD患者淋巴瘤风险升高相关,而维得利珠单抗、乌司奴单抗和JAK抑制剂未检测到风险增加。
研究设计与样本
- 在法国国家健康数据系统(SNDS)2009至2024年全部IBD患者队列中开展巢式病例对照研究。
- 新发淋巴瘤病例按日历年、年龄、性别和IBD病程匹配最多50名对照。
主要发现
- 当前使用硫嘌呤类与淋巴瘤风险升高相关(aOR 2.36;95%CI 2.00-2.79)。
- 当前使用抗TNF与淋巴瘤风险升高相关(aOR 1.72;95%CI 1.45-2.05)。
- 抗TNF联合硫嘌呤/甲氨蝶呤时风险超过三倍(aOR 3.44;95%CI 2.62-4.51)。
- 硫嘌呤停药后风险持续至3年,抗TNF停药后持续至1年;硫嘌呤存在剂量反应关系。
- 硫嘌呤与霍奇金淋巴瘤和高级别非霍奇金淋巴瘤相关,抗TNF增加所有亚型风险;维得利珠单抗、乌司奴单抗和JAK抑制剂未与风险增加相关。
关键数值与推荐
- 当前硫嘌呤暴露aOR 2.36(95%CI 2.00-2.79)。
- 当前抗TNF暴露aOR 1.72(95%CI 1.45-2.05)。
- 抗TNF联合硫嘌呤/甲氨蝶呤aOR 3.44(95%CI 2.62-4.51)。
- 维得利珠单抗、乌司奴单抗和JAK抑制剂未与淋巴瘤风险增加相关。
- 甲氨蝶呤与淋巴瘤风险增加相关,但该关联在敏感性分析中不一致。
临床怎么用
- 对IBD患者选择治疗时,应将淋巴瘤风险纳入硫嘌呤和抗TNF的获益-风险评估。
- 抗TNF联合硫嘌呤/甲氨蝶呤时淋巴瘤风险显著升高,需谨慎评估联合治疗的必要性。
- 维得利珠单抗、乌司奴单抗和JAK抑制剂在本研究中未显示淋巴瘤风险增加,可作为需考虑淋巴瘤风险患者的治疗选择参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Current evidence does not allow firm conclusions regarding lymphoma risk across the expanding therapeutic arsenal for inflammatory bowel disease. We aimed to evaluate lymphoma risk across inflammatory bowel disease treatments using a nationwide, population-based database. METHODS: We conducted a nested case-control study within a cohort of all patients with inflammatory bowel disease recorded in the French National Health Data System (SNDS) between 2009 and 2024. Incident lymphoma cases were matched to up to 50 controls by calendar year, age, sex, and inflammatory bowel disease duration. Exposures included thiopurines, methotrexate, anti-tumor necrosis factors, vedolizumab, ustekinumab, and Janus kinase inhibitors. Adjusted odds ratios were estimated using conditional logistic regression, accounting for sociodemographic factors, inflammatory bowel disease characteristics, and comorbidities. RESULTS: Among 422,793 patients with inflammatory bowel disease, 1238 lymphoma cases and 52,565 matched controls were included. Current exposures to thiopurines (adjusted odds ratio, 2.36; 95% confidence interval, 2.00-2.79) and anti-tumor necrosis factors (adjusted odds ratio, 1.72; 95% confidence interval, 1.45-2.05) were associated with increased lymphoma risk. The risk was more than tripled for combination of anti-tumor necrosis factors and thiopurines/methotrexate (adjusted odds ratio, 3.44; 95% confidence interval, 2.62-4.51). Risk persisted up to 3 years after thiopurine discontinuation and 1 year after anti-tumor necrosis factor discontinuation. A dose-response relationship was observed for thiopurines. Thiopurines were associated with Hodgkin lymphoma and high-grade non-Hodgkin lymphoma, whereas anti-tumor necrosis factors increased risk across all lymphoma subtypes, including low-grade non-Hodgkin lymphoma. In contrast, vedolizumab, ustekinumab, and Janus kinase inhibitors were not associated with increased lymphoma risk. Methotrexate was associated with increased lymphoma risk, although this association was not consistent across sensitivity analyses. CONCLUSIONS: These findings confirm the increased lymphoma risk associated with thiopurines and anti-tumor necrosis factors in inflammatory bowel disease, whereas no increased risk was detected for vedolizumab, ustekinumab, and Janus kinase inhibitors.
引用
- Meyer A, Weill A, Carbonnel F, et al. Risk of Lymphoma Associated With Biologics and Immunosuppressants in Inflammatory Bowel Disease Patients: A Nationwide Nested Case-Control Study. Clin Gastroenterol Hepatol. 2026. PMID: 42269996. doi:10.1016/j.cgh.2026.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。